

Press release

January 26, 2016

Fina Biotech announces that two new patents have been granted in 2015 in the United States and in Canada, both belonging to the patent family “**BLADDER CANCER DIAGNOSIS AND/OR PROGNOSIS METHOD**”.

In the United States the patent 9,097,715 has been granted by the United States Patent and Trademark Office (USPTO). The Patent Term Adjustment determined by the USPTO is 1,289 days which allows the patent to be in force until December 15th, 2030. In Canada the patent has been granted by the Canadian Intellectual Property Office (CIPO) under application number 2,693,847.

The object of this family of patents relates to a non-invasive bladder cancer diagnosis and/or prognosis method based on the detection and quantification in spontaneous urine of the gene expression of certain genes and/or combinations thereof acting as genetic markers of said disease. Likewise, the use of said genes as bladder cancer diagnosis and/or prognosis genetic markers is an object of the present invention, developed by Fina Biotech in collaboration Dr. Antonio Alcaraz and his team at the Hospital Clinic de Barcelona (Spain). Another object of the patent also relates to a bladder cancer diagnosis and/or prognosis kit based on the use of said genes as genetic markers of the disease.

These new patents strengthen the intellectual property portfolio of Fina Biotech and confirm the company strategic commitment in developing non-invasive diagnostic tools useful for patients, doctors and healthcare providers.

Fina Biotech S.L. (www.finabiotech.es) is a spin-off of Laboratorios Indas (www.indas.com), with a strong pipeline of biotechnology projects and a proven track record in product development. Fina Biotech has invested close to €12 million in 28 projects in the diagnostics and cell therapy fields, most of them in partnership with public and private institutions, laboratories and universities. A product developed by Fina Biotech, a diagnostic test for male infertility (Halosperm[®]) is already marketed. A bladder cancer diagnostic test based on RT-qPCR technology has already been validated in clinical studies and has proven to have better sensitivity and specificity than competitive products (12-gene signature results: SN=79% and SP=93%).

Biofina Diagnostics S.L. (www.biofinadx.com) is a new corporate vehicle incorporated to further develop and take the bladder cancer diagnostic test to the market. The company holds the exclusive exploitation and commercialization rights on Fina Biotech’s patents protecting the diagnostic method. Biofina Diagnostics is currently exploring partnering opportunities that support the introduction of the test into the market both in Europe and the United States.

Fina Biotech S.L.

Headquarters and offices: Calle Camino de las Huertas, 2, Edif. 1
28223 Pozuelo de Alarcón (Madrid) SPAIN – Tel: +34 91 799 15 64
www.finabiotech.es